​

Kymera Therapeutics (KYMR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

KYMR Stock Forecast

Kymera Therapeutics (KYMR) stock forecast, based on 27 Wall Street analysts, predicts a 12-month average price target of $128.00, with a high of $155.00 and a low of $97.00. This represents a 15.76% increase from the last price of $110.57.

- $40 $80 $120 $160 $200 High: $155 Avg: $128 Low: $97 Last Closed Price: $110.57

KYMR Stock Rating

Kymera Therapeutics stock's rating consensus is Buy, based on 27 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 23 Buy (85.19%), 4 Hold (14.81%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 27 0 4 23 Strong Sell Sell Hold Buy Strong Buy

KYMR Price Target Upside V Benchmarks

TypeNameUpside
StockKymera Therapeutics15.76%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts5839
Avg Price Target$135.00$124.63$104.51
Last Closing Price$110.57$110.57$110.57
Upside/Downside22.09%12.72%-5.48%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 265171--23
Jun, 265181--24
May, 265171--23
Apr, 265161--22
Mar, 265171--23
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 16, 2026Joseph CatanzaroMizuho Securities$140.00$114.1222.68%26.62%
Jul 13, 2026Brian AbrahamsRBC Capital$115.00$119.35-3.64%4.01%
Jun 29, 2026Srikripa DevarakondaTruist Financial$136.00$108.1225.79%23.00%
Jun 26, 2026Edward NashCanaccord Genuity$129.00$116.4610.77%16.67%
Jun 26, 2026Kalpit PatelB.Riley Financial$155.00$116.4633.09%40.18%
Jun 08, 2026Leah Rush CannLoop Capital Markets$97.00$73.9531.17%-12.27%
May 06, 2026Edward NashCanaccord Genuity$106.00$82.7128.16%-4.13%
Apr 30, 2026Judah FrommerMorgan Stanley$119.00$80.7347.40%7.62%
Feb 26, 2026Judah FrommerMorgan Stanley$123.00$95.0329.43%11.24%
Feb 26, 2026Brian AbrahamsRBC Capital$108.00$91.8717.56%-2.32%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 13, 2026RBC CapitalOutperformSector Performdowngrade
Jun 29, 2026B. RileyBuyBuyhold
Jun 08, 2026Brookline CapitalBuyBuyhold
Apr 30, 2026Morgan StanleyOverweightOverweighthold
Mar 02, 2026StephensOverweightOverweighthold
Mar 02, 2026CitigroupBuyBuyhold
Feb 26, 2026Morgan StanleyOverweightOverweighthold
Feb 26, 2026RBC CapitalOutperformOutperformhold
Jan 06, 2026Wolfe ResearchEqual-WeightPeer Performdowngrade
Dec 22, 2025B. RileyBuyBuyhold

Financial Forecast

EPS Forecast

$-9 $-8 $-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.09$-2.87$-2.52$-2.98$-3.69---
Avg Forecast$-1.86$-2.90$-2.64$-2.82$-3.06$-3.54$-3.57$-2.90
High Forecast$-0.57$-0.64$-1.81$-2.15$-1.42$-2.49$-2.30$-0.03
Low Forecast$-4.13$-7.72$-3.11$-3.15$-4.14$-5.73$-4.68$-8.26
Surprise %12.37%-1.03%-4.55%5.67%20.59%---

Revenue Forecast

$0 $90M $180M $270M $360M $450M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$72.83M$46.83M$78.59M$47.07M$39.20M---
Avg Forecast$83.71M$50.19M$69.37M$53.87M$68.16M$63.62M$88.05M$181.58M
High Forecast$162.04M$114.40M$118.35M$107.40M$170.65M$64.51M$89.94M$439.66M
Low Forecast$39.15M$20.17M$39.77M$42.96M$18.28M$62.72M$86.16M$43.53M
Surprise %-12.99%-6.70%13.30%-12.62%-42.49%---

Net Income Forecast

$-500M $-400M $-300M $-200M $-100M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-100.22M$-154.81M$-146.96M$-223.86M$-311.40M---
Avg Forecast$-78.75M$-127.85M$-146.96M$-167.47M$-162.27M$-319.20M$-203.93M$-169.39M
High Forecast$-63.00M$-102.28M$-117.57M$-125.71M$-83.08M$-145.22M$-134.43M$-1.97M
Low Forecast$-94.50M$-153.42M$-176.35M$-184.14M$-241.47M$-334.37M$-273.43M$-482.36M
Surprise %27.25%21.08%-33.67%91.90%---

KYMR Forecast FAQ

Is Kymera Therapeutics stock a buy?

Kymera Therapeutics stock has a consensus rating of Buy, based on 27 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 23 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Kymera Therapeutics is a favorable investment for most analysts.

What is Kymera Therapeutics's price target?

Kymera Therapeutics's price target, set by 27 Wall Street analysts, averages $128 over the next 12 months. The price target range spans from $97 at the low end to $155 at the high end, suggesting a potential 15.76% change from the previous closing price of $110.57.

How does Kymera Therapeutics stock forecast compare to its benchmarks?

Kymera Therapeutics's stock forecast shows a 15.76% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Kymera Therapeutics over the past three months?

  • July 2026: 21.74% Strong Buy, 73.91% Buy, 4.35% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 20.83% Strong Buy, 75.00% Buy, 4.17% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 21.74% Strong Buy, 73.91% Buy, 4.35% Hold, 0% Sell, 0% Strong Sell.

What is Kymera Therapeutics’s EPS forecast?

Kymera Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.54, marking a -4.07% decrease from the reported $-3.69 in 2025. Estimates for the following years are $-3.57 in 2027, and $-2.9 in 2028.

What is Kymera Therapeutics’s revenue forecast?

Kymera Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $63.62M, reflecting a 62.28% increase from the reported $39.2M in 2025. The forecast for 2027 is $88.05M, and $181.58M for 2028.

What is Kymera Therapeutics’s net income forecast?

Kymera Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-319M, representing an 2.50% increase from the reported $-311M in 2025. Projections indicate $-204M in 2027, and $-169M in 2028.